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ABSTRACT 
Aldose reductase inhibitors improve nerve 
biochemistry, function, and structure in diabetic 
animals and increase nerve conduction in diabetic 
patients. Nevertheless, it has been difficult to 
demonstrate a benefit from these agents in patients 
with clinically overt diabetic neuropathy. Direct 
measurement of the nerve tissue penetration and 
biochemical and biological potency of these 
compounds is essential to fully understand and 
evaluate their effectiveness. Human sural nerve 
biopsies obtained from diabetic neuropathic 
patients undergoing treatment with an aldose 
reductase inhibitor revealed a reduction in 
intermediates of the polyol pathway. Specific 
morphologic lesions that correlate with the degree 
of clinical and electrophysiologic impairment also 
were identified. Morphologic evaluation of sural 
nerve biopsies obtained after aldose reductase 
inhibitor treatment suggests that these 
biochemically effective compounds ameliorate 
clinically relevant structural lesions in patients 
with diabetic neuropathy. (Journal of Diabetes and 
Its Complications 6;1:35-38, 1992.) 
0 
INTRODUCTION 
Only a decade ago, the long-term neuro- 
logic complications of diabetes mellitus 
were attributed to nerve degeneration or 
demyelination. More recently, attention 
has focused on a potentially reversible metabolic dis- 
order in which the enzyme, aldose reductase, in re- 
sponse to hyperglycemia, promotes increased inter- 
cellular conversion of glucose to sorbitol and de- 
creased uptake of the cyclic hexanol, myo-inositol.‘,2 
The depletion of myo-inositol in nerve tissue appears 
responsible for a variety of metabolic and electrophys- 
iologic alterations, including a decrease in sodium- 
crease in energy consumption of the nerve tissue, an- 
potassium adenosine triphosphatase (ATPase), a de- 
dalterations in nerve conduction. As a result, it ap- 
pears that intra-axonal sodium accumulates at the 
node of Ranvier and causes localized swelling and the 
characteristic lesion, axo-glial dysjunction. The phar- 
macologic inhibition of aldose reductase represents an 
opportunity to reduce sorbitol accumulation and to 
arrest or reverse nerve damage that occurs as a com- 
plication of diabetes mellitus. 
Aldose reductase inhibitors block the conversion of 
glucose to sorbitol, the depletion of myo-inositol, and 
the impairment of sodium-potassium ATPase;2 how- 
ever, their effectiveness in ameliorating clinically 
overt diabetic neuropathy is uncertain. Short-term 
studies with aldose reductase inhibitors have not been 
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tom that focus on outcome measures of nerve fiber 
structure and density are more likely to provide in- 
sights into the etiology and pathology of chronic 
symptomatic diabetic neuropathies. Further, detailed 
measurements of changes in nerve fiber parameters 
can provide an effective means of comparing different 
aldose reductase inhibitors. 
STRUCTURAL ABNORMALITIES ASSOCIATED 
WITH DIABETIC NEUROPATHY 
Three structural abnormalities, the so-called triopathy 
of diabetic neuropathy, are observed in patients with 
diabetic neuropathy: fiber loss, fiber atrophy, and 
specific fiber lesions. Patients with diabetic polyneu- 
ropathy demonstrate a reduced number of functional 
myelinated nerve fibers, and those fibers that survive 
are reduced in size. This decrease in axonal size is 
exhibited as a reduction in cross-sectional area. 
The three components of the triopathy provide a 
series of measurable and quantifiable morphometric 
parameters which exhibit a relationship to the dura- 
tion of diabetes in patients with diabetic neuropathy. 
For example, fiber loss can be quantified as a decrease 
in fiber density, measured as the number of fibers per 
square millimeter of a cross-sectional area of nerve. 
Fiber atrophy can be characterized several ways; these 
include a decrease in the mean fiber size, an increase 
in the myelin endpoint, or a decrease in the ratio of 
axonal to myelin area. Fiber atrophy in an axon can be 
demonstrated by changes in the relationship between 
the area of the axon and the number of myelin lamella. 
Because myelin assumes a wrinkled appearance when 
atrophied, increases in the percentage of wrinkled 
myelin is also evidence of fiber atrophy. 
Specific fiber lesions can be identified by the accu- 
mulation of a series of discrete abnormalities on mi- 
crographs or as a decrease in the percentage of nor- 
mal-appearing fibers. Many of these changes occur 
initially at the node of Ranvier, and one of the earliest 
lesions is the axo-glial dysjunction. This lesion is de- 
scribed as a loss of tight junction complexes that nor- 
mally maintain the integrity of the node of Ranvier by 
anchoring terminal loops of myelin to the axolemma. 
More advance abnormalities that occur are swelling 
of the node and perinodal region and perinodal demy- 
elination followed by remyelination. Frequently, in- 
creased segmental demyelination also occurs. In re- 
sponse to these injuries, increased neurofiber regen- 
eration may be demonstrated with regenerating 
sprouts occupying the area derived from the previ- 
ously degenerated axon. 
It is possible to quantify the overall degree of pa- 
thology that is present by using a variety of different 
scoring systems. One method uses a compound pa- 
rameter score (density, atrophy, and lesions) that is 
normalized for age and gender.” This approach 
clearly distinguishes patients with diabetic peripheral 
polyneuropathy from a normal reference population. 
Further, diabetics without symptomatic peripheral 
neuropathy appear to be grouped with the larger nor- 
mal population, rather than with the patients having 
diabetic polyneuropathy. This system allows one to 
differentiate between neuropathic and non-neuro- 
pathic diabetics on the basis of a threshold of pa- 
thology. 
A similar system has been developed at our institu- 
tion. It is called the index of normality and is obtained 
from the product of fiber density and the percentage 
of fibers with normal appearance.2 This method dif- 
fers from that of Dyck et al. lo in that it does not correct 
for age and gender. Using this and other quantitative 
measures, we have investigated the effects of differ- 
ent aldose reductase inhibitors on nerve fiber mor- 
phology. 
THE EFFECTS OF ALDOSE REDUCTASE 
INHIBITORS ON NERVE FIBER MORPHOLOGY 
Three long-term, double-blind, randomized, con- 
trolled studies of aldose reductase inhibitors are avail- 
able for the morphologic examination of human nerve 
specimens. In each study, sural nerve biopsies were 
obtained prior to and after at least 12 months of ther- 
apy, and morphometric techniques were employed to 
quantify nerve fiber changes. 
Sorbinil North American Neuropathy Trial. Sural 
nerve biopsy specimens were obtained from 16 dia- 
betics with symptomatic peripheral polyneuropathy 
prior to and 12 months after sorbinil250 mg per day 
(n = 10) or placebo (n = 6) therapyq2 Although the 
mean sural nerve sorbitol concentration in sorbinil- 
treated patients was significantly decreased when 
compared with baseline measurements, no significant 
change was noted in placebo-treated patients. Of 
note, sural nerve sorbitol levels actually increased in 
one patient who discontinued the drug. This clearly 
indicates that sorbinil enters peripheral nerve tissue 
at the site of aldose reductase and decreases sorbitol 
accumulation by inhibiting polyol activity. 
A number of morphometric findings were available 
from this study. Fiber loss was partially corrected, as 
indicated by a statistically significant increase in nerve 
fiber density in sorbinil-treated patients and no 
change in the placebo-treated patients. The increase 
in nerve fiber density was accounted for by a several- 
fold increase in nerve fiber regeneration. It should be 
noted that the failure to observe deterioration of nerve 
fiber density in placebo-treated patients during the 
la-month study is consistent with the slow progres- 
sion of diabetic polyneuropathy. 
The number of specific fiber lesions, including axo- 
glial dysjunction, were increased at baseline in both 
the placebo and sorbinil groups. During the study, 
these returned to normal in the sorbinil group but 
1 Diab Comp 1992; 6:l ALDOSE REDUCTASE INHIBITORS 37 
were unchanged in the placebo group. Similarly, axo- 
nal atrophy, as evidenced by either the axon/myelin 
ratio or the presence of excessive myelin wrinkling, 
was improved after sorbinil, indicating that aldose re- 
ductase inhibition exerted a beneficial effect on fiber 
atrophy. Sorbinil-treated patients had an increase in 
the overall percentage of nerve fibers that showed a 
normal appearance due to the repair of previously 
damaged fibers. This increase in normality was cor- 
rected for the increase in regeneration, and thus, ac- 
tually represents repair of previously damaged 
neurons. 
When this data was combined into the overall score 
for index of normality, an improvement in the index 
of normality was noted with sorbinil, as compared 
with no change in the placebo group. This indicates 
that biochemically effective aldose reductase inhibi- 
tors appear to produce consistent improvement in the 
structural abnormalities associated with diabetic neu- 
ropathy. 
Statil North American Neuropathy Trial. In this 
double-blind, controlled study, sural nerve biopsy 
specimens were obtained from 47 neuropathic dia- 
betics prior to and 18 months after treatment with 
statil600 mg per day (n = 21) or placebo (n = 26). *I 
No significant change was observed in nerve sorbitol 
concentrations or in the index of normality in either 
statil- or placebo-treated patients. This suggests that 
statil did not achieve tissue levels in the peripheral 
nerve that were adequate to inhibit aldose reductase. 
Consistent with the lack of a biochemical effect, there 
was no improvement in any morphometric param- 
eters with statil compared with placebo. 
Tolrestat United States Trial. This was an open- 
label study in which single sural nerve biopsies were 
obtained after 3.5-4 years of treatment with tolres- 
tat. l2 Patients were then entered into a 12-month dou- 
ble-blind, randomized continuation or withdrawal 
treatment period. A sural nerve biopsy was obtained 
at the end of the 12-month period. Eighteen neuro- 
pathic patients with long-standing diabetes (duration 
of approximately 25 years) who were treated for 3-5 
years with tolrestat 200-400 mg per day in the open- 
label study were randomized to continue receiving 
tolrestat (n = 9) or were switched to placebo treat- 
ment (n = 9). These patients tended to be older and 
predominantly insulin-dependent diabetics; thus, it 
can be assumed that they had advanced peripheral 
neuropathy prior to entering the study. 
Sorbitol and glucose concentration measurements 
from sural nerve biopsies obtained prior to and after 
12 months of therapy showed that tolrestat inhibited 
sural nerve sorbitol accumulation. In placebo-treated 
patients, there was a glucose-mediated rise in sural 
nerve sorbitol levels. Peak sorbitol concentrations 
reached 3.5-5.5 nmol/mg protein in patients whose 
glucose nerve concentrations were between 250 and 
350 nmol/mg protein. In contrast, sorbitol concentra- 
tions in tolrestat-treated patients reached a plateau at 
between 1 and 1.5 nmol/mg protein, despite sural 
nerve glucose concentrations that ranged from less 
than 75 to almost 250 nmol/mg protein. A decrease in 
the glucose-mediated rise in fructose also was noted 
with tolrestat treatment but not with placebo, which 
indicates a significant inhibition of the polyol pathway 
by tolrestat. 
No statistically significant differences were revealed 
in a comparison of nerve morphometry in patients 
receiving open-label tolrestat who were randomly 
reassigned to double-blind treatment with tolrestat or 
placebo. This is expected based on the slow rate of 
progression of diabetic neuropathy. There was, how- 
ever, a statistically significant relationship between 
the duration of treatment with tolrestat and the extent 
of nerve fiber regeneration. Furthermore, a negative 
correlation was observed between the duration of 
treatment with tolrestat and axo-glial dysjunction, 
which suggests that prolonged treatment with tolres- 
tat stimulated fiber regeneration and prevented wors- 
ening or improved axo-glial dysjunction. 
A more-extensive evaluation of nerve fiber mor- 
phology was conducted using tolrestat-treated pa- 
tients from the United States study and comparing 
them with two reference populations of untreated dia- 
betic patients entering other aldose reductase inhibi- 
tor trials. Recently, this reference population was ex- 
panded by the addition of younger patients with a 
shorter duration of diabetes. 
Three statistical approaches were used to correct for 
differences in age and duration of diabetes between 
the groups. The data for the reference populations 
were adjusted with age and nondiabetic controls for 
each of the morphometric parameters. Data also were 
adjusted for age and duration of diabetes. Finally, a 
complex analysis of the expanded diabetic reference 
population was performed using a quadratic surface 
adjustment paradigm to look at within group reIation- 
ships regarding both age and duration of diabetes. 
A significant increase in fiber regeneration was ob- 
served in untreated diabetics when compared with 
nondiabetic controls. This increase would be expected 
from any patient with diabetic peripheral polyneurop- 
athy. However, tolrestat treatment was associated 
with a fourfold increase in fiber regeneration com- 
pared with untreated diabetics. Axo-glial dysjunction 
was significantly increased in untreated diabetics with 
polyneuropathy, as compared with nondiabetic con- 
trols, and was essentially normal after tolrestat treat- 
ment. This indicates that tolrestat had corrected the 
increase in axo-glial dysjunction that was seen in the 
other reference populations. SimiIarIy, segmental de- 
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myelination, which was increased in the reference 
population compared with nondiabetic controls, was 
normalized in patients who were treated with tolres- 
tat for 3.5-4 years. 
Analysis of the effects of tolrestat on fiber density 
was more complex because fiber density is a reflection 
of the course of diabetes over many years, which 
makes adjustments for age and duration of diabetes 
difficult. Compared with untreated diabetics, there 
was a trend for improvement in fiber density in the 
tolrestat group. But when the larger reference popula- 
tion-which included many patients with less severe 
neuropathy-was used for comparison, there ap- 
peared to be a decrease in fiber density in the tolrestat 
group; thus, on the basis of these patient populations, 
it is not possible to make a conclusion about the effect 
of tolrestat on nerve fiber density. 
CONCLUSION 
These data support the contention that nerve fiber 
regeneration is a sensitive and consistent marker of 
tissue-specific biological activity of aldose reductase 
inhibitors in clinical and overt diabetic periphera1 
polyneuropathy. Data from long-term studies with 
two of the three aldose reductase inhibitors presented 
herein demonstrate a broad spectrum of morphomet- 
ric improvements that are indicative of overall tissue 
repair. This data strongly argues for the role of the 
polyol pathway in the pathogenesis of clinically overt 
diabetic peripheral polyneuropathy and maintains the 
hope that treatment with aldose reductase inhibitors 
will reduce the progression or improve and partially 
reverse neuropathy even at late stages when the pa- 
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